Celldex Therapeutics Inc (CLDX): Price Now Near $54.64; Daily Chart Shows An Uptrend on 50 Day Basis

The Hourly View for CLDX

At the time of this writing, CLDX (Get Ratings)’s price is up $0.23 (0.42%) from the hour prior. It’s been a feast for bulls operating on an hourly timeframe, as CLDX has now gone up 4 of the past 5 hours. If you’re a trend trader, consider that the strongest clear trend on the hourly chart exists on the 20 hour timeframe. Of note is that the 20 hour changed directions on CLDX; it is now pointing down. The moving averages on the hourly timeframe suggest a choppiness in price, as the 20, 50, 100 and 200 are all in a mixed alignment — meaning the trend across timeframes is inconsistent, indicating a potential opportunity for rangebound traders.

Out of Pharmaceutical Products stocks, CLDX ranks 70th in regards to today’s price percentage change.

CLDX’s Technical Outlook on the Daily Chart

Currently, CLDX’s price is up $0.5 (0.92%) from the day prior. This is a reversal of the price action on the previous day, in which price moved down. Regarding the trend, note that the strongest trend exists on the 20 day timeframe. The moving averages on the daily timeframe suggest a bullishness in price, as the 20, 50, 100 and 200 are all in a bullish alignment — meaning the shorter durations are above the longer duration averages, implying a sound upward trend. The chart below shows CLDX’s price action over the past 90 days.



CLDX: Daily RSI Analysis

  • CLDX’s RSI now stands at 73.2558.
  • Note: CLDX and RSI appear to be diverging in terms of their respective trends, with CLDX rising at a slower rate than RSI.

For CLDX News Traders

Investors and traders in CLDX may be particularly interested in the following story that came out in the past day:

Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study

HAMPTON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CDX-0159 in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. The Company intends to utilize the subcutaneous formulation of CDX-0159 in its Phase 2 program in chronic urt

Want More Great Investing Ideas?

9 “MUST OWN” Growth Stocks for 2021

5 WINNING Stock Chart Patterns

7 Best ETFs for the NEXT Bull Market